Driving the Advancement of Cutting-edge Science & Technology
Improving next generation medicines
Both our protein-based nanoparticles and Matrix-M® adjuvant are the basis of our promising pipeline programs and provide a strong foundation for innovation. We have initiated development work on novel Matrix formulations, different regimens and dosing schedules with the potential to further differentiate and potentially improve next generation medicines. We aim to create opportunities for targeted approaches and advancements in therapeutic areas beyond infectious diseases.
Beyond COVID-19, influenza and our combination of the two, our approach has yielded four highly differentiated programs in unmet need areas: respiratory syncytial virus (RSV), H5N1 avian pandemic influenza, shingles and C. difficile.
We leverage a discovery model that is driven by artificial intelligence (AI) and machine learning. This approach enables us to leverage our deep in-house expertise coupled with extensive published scientific literature and modern computational techniques to optimize our product candidates’ efficacy, safety and tolerability.
Publications
Novavax has been at the forefront of R&D for decades and has contributed a wealth of information to the body of scientific knowledge. Learn more about our science and technology in our publications.